---
title: "Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292512512.md"
description: "Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. to $237.79, implying a 2% upside from the July 10 closing price. The consensus rating remains 'Buy' among 20 covering analysts, with forecasts ranging from $180 to $265 per share."
datetime: "2026-07-13T16:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292512512.md)
  - [en](https://longbridge.com/en/news/292512512.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292512512.md)
---

# Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside

-   According to estimates from 14 analysts, Charles River Laboratories International, Inc. stock's average price target has risen from $232.5 to $235.64, with forecasts ranging from $180 to $265 per share
-   Based on the Jul. 10 closing price, the updated target implies approximately 1% potential upside
-   Consensus rating remains at “Buy” across 20 covering analysts, with 15 Buys, 4 Holds and 1 Sells

Explore more price target data and ratings for Charles River Laboratories International, Inc. on the , and track all previous and future analyst recommendations for Charles River Laboratories International, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [The Manufacturers Life Insurance Company Grows Position in Charles River Laboratories International, Inc. $CRL](https://longbridge.com/en/news/294937463.md)
- [CRL: Double-digit growth across all segments and regions, with EBITDA margin up 350 bps year-over-year](https://longbridge.com/en/news/294853655.md)
- [Charles River Laboratories Earnings Preview: What to Expect](https://longbridge.com/en/news/293235736.md)
- [Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer | AAPG Stock News](https://longbridge.com/en/news/294616973.md)
- [Joby (JOBY) vs. Archer (ACHR): Why Analysts See 150%+ Upside in One eVTOL Stock, but Caution About the Other, Ahead of Q2 Earnings](https://longbridge.com/en/news/294587017.md)